Study Reveals How GLP-1 Drugs May Reduce Pleasure-Driven Eating
Recent research funded by the National Institutes of Health (NIH) has shed light on the effects of newer oral GLP-1 medications, such as orforglipron and danuglipron, on the brain's reward circuits. These drugs, part of a class that includes well-known weight-loss and diabetes medications like semaglutide and Ozempic, have been shown to reduce hedonic feeding—eating for enjoyment rather than energy needs—in mice. This study highlights a previously unrecognized pathway through which these medications may influence eating behavior.
The research team from the University of Virginia focused on small-molecule GLP-1 receptor agonists, which differ from larger peptide medications. The study aimed to understand how these oral drugs interact with the brain, particularly in areas related to pleasure and reward. The findings revealed that while these medications affect regions associated with appetite regulation, they also activate the central amygdala, a deeper brain region involved in desire and reward. This activation appears to suppress dopamine release in key areas of the brain's reward system during pleasure-driven eating.
Dr. Lorenzo Leggio, Clinical Director of NIH's National Institute on Drug Abuse, emphasized the importance of understanding the neural mechanisms behind these medications as their accessibility increases. The study suggests that oral GLP-1 drugs may not only curb hunger but also diminish the pleasurable signals that make certain foods appealing.
As researchers continue to explore the implications of these findings, they aim to investigate whether these next-generation GLP-1 medications could also help reduce cravings for substances beyond food, potentially addressing issues related to substance use disorders. The study was supported by various NIH grants and is not yet associated with clinical trials for product approval.




